Patient-reported outcomes in OlympiA: a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer

Purpose - The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and...

Full description

Saved in:
Bibliographic Details
Main Authors: Ganz, Patricia A. (Author) , Bandos, Hanna (Author) , Španić, Tanja (Author) , Friedman, Sue (Author) , Müller, Volkmar (Author) , Kuemmel, Sherko (Author) , Delaloge, Suzette (Author) , Brain, Etienne (Author) , Toi, Masakazu (Author) , Yamauchi, Hideko (Author) , de Dueñas, Eduardo-M. (Author) , Armstrong, Anne (Author) , Im, Seock-Ah (Author) , Song, Chuan-gui (Author) , Zheng, Hong (Author) , Sarosiek, Tomasz (Author) , Sharma, Priyanka (Author) , Geng, Cuizhi (Author) , Fu, Peifen (Author) , Rhiem, Kerstin (Author) , Frauchiger-Heuer, Heike (Author) , Wimberger, Pauline (Author) , t'Kint de Roodenbeke, Daphné (Author) , Liao, Ning (Author) , Goodwin, Annabel (Author) , Chakiba-Brugère, Camille (Author) , Friedlander, Michael (Author) , Lee, Keun Seok (Author) , Giacchetti, Sylvie (Author) , Takano, Toshimi (Author) , Henao-Carrasco, Fernando (Author) , Virani, Shamsuddin (Author) , Valdes-Albini, Frances (Author) , Domchek, Susan M. (Author) , Bane, Charles (Author) , McCarron, Edward C. (Author) , Mita, Monica (Author) , Rossi, Giovanna (Author) , Rastogi, Priya (Author) , Fielding, Anitra (Author) , Gelber, Richard D. (Author) , Scheepers, Elsemieke D. (Author) , Cameron, David (Author) , Garber, Judy (Author) , Geyer, Charles E. (Author) , Tutt, Andrew N.J. (Author)
Format: Article (Journal)
Language:English
Published: February 1, 2024
In: Journal of clinical oncology
Year: 2024, Volume: 42, Issue: 11, Pages: 1288-1300
ISSN:1527-7755
DOI:10.1200/JCO.23.01214
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1200/JCO.23.01214
Verlag, kostenfrei, Volltext: https://ascopubs.org/doi/10.1200/JCO.23.01214
Get full text
Author Notes:Patricia A. Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Sherko Kuemmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Hideko Yamauchi, Eduardo-M. de Dueñas, Anne Armstrong, Seock-Ah Im, Chuan-gui Song, Hong Zheng, Tomasz Sarosiek, Priyanka Sharma, Cuizhi Geng, Peifen Fu, Kerstin Rhiem, Heike Frauchiger-Heuer, Pauline Wimberger, Daphné t'Kint de Roodenbeke, Ning Liao, Annabel Goodwin, Camille Chakiba-Brugère, Michael Friedlander, Keun Seok Lee, Sylvie Giacchetti, Toshimi Takano, Fernando Henao-Carrasco, Shamsuddin Virani, Frances Valdes-Albini, Susan M. Domchek, Charles Bane, Edward C. McCarron, Monica Mita, Giovanna Rossi, Priya Rastogi, Anitra Fielding, Richard D. Gelber, Elsemieke D. Scheepers, David Cameron, Judy Garber, Charles E. Geyer, and Andrew N.J. Tutt

MARC

LEADER 00000caa a2200000 c 4500
001 1911195921
003 DE-627
005 20250716214609.0
007 cr uuu---uuuuu
008 241209s2024 xx |||||o 00| ||eng c
024 7 |a 10.1200/JCO.23.01214  |2 doi 
035 |a (DE-627)1911195921 
035 |a (DE-599)KXP1911195921 
035 |a (OCoLC)1528014740 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ganz, Patricia A.  |e VerfasserIn  |0 (DE-588)1013229886  |0 (DE-627)704985705  |0 (DE-576)346735254  |4 aut 
245 1 0 |a Patient-reported outcomes in OlympiA  |b a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer  |c Patricia A. Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Sherko Kuemmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Hideko Yamauchi, Eduardo-M. de Dueñas, Anne Armstrong, Seock-Ah Im, Chuan-gui Song, Hong Zheng, Tomasz Sarosiek, Priyanka Sharma, Cuizhi Geng, Peifen Fu, Kerstin Rhiem, Heike Frauchiger-Heuer, Pauline Wimberger, Daphné t'Kint de Roodenbeke, Ning Liao, Annabel Goodwin, Camille Chakiba-Brugère, Michael Friedlander, Keun Seok Lee, Sylvie Giacchetti, Toshimi Takano, Fernando Henao-Carrasco, Shamsuddin Virani, Frances Valdes-Albini, Susan M. Domchek, Charles Bane, Edward C. McCarron, Monica Mita, Giovanna Rossi, Priya Rastogi, Anitra Fielding, Richard D. Gelber, Elsemieke D. Scheepers, David Cameron, Judy Garber, Charles E. Geyer, and Andrew N.J. Tutt 
264 1 |c February 1, 2024 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.12.2024 
520 |a Purpose - The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment. - Methods - Data were collected before random assignment, and at 6, 12, 18, and 24 months. The primary end point was fatigue, measured with the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary end points, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 item, included nausea and vomiting (NV), diarrhea, and multiple functional domains. Scores were compared between treatment groups using mixed model for repeated measures. Two-sided P values <.05 were statistically significant for the primary end point. All secondary end points were descriptive. - Results - One thousand five hundred and thirty-eight patients (NACT: 746, ACT: 792) contributed to the analysis. Fatigue severity was statistically significantly greater for OL versus PL, but not clinically meaningfully different by prespecified criteria (≥3 points) at 6 months (diff OL v PL: NACT: -1.3 [95% CI, -2.4 to -0.2]; P = .022; ACT: -1.3 [95% CI, -2.3 to -0.2]; P = .017) and 12 months (NACT: -1.6 [95% CI, -2.8 to -0.3]; P = .017; ACT: -1.3 [95% CI, -2.4 to -0.2]; P = .025). There were no significant differences in fatigue severity between treatment groups at 18 and 24 months. NV severity was worse in patients treated with OL compared with PL at 6 months (NACT: 6.0 [95% CI, 4.1 to 8.0]; ACT: 5.3 [95% CI, 3.4 to 7.2]) and 12 months (NACT: 6.4 [95% CI, 4.4 to 8.3]; ACT: 4.5 [95% CI, 2.8 to 6.1]). During treatment, there were some clinically meaningful differences between groups for other symptoms but not for function subscales or global health status. - Conclusion - Treatment-emergent symptoms from OL were limited, generally resolving after treatment ended. OL- and PL-treated patients had similar functional scores, slowly improving during the 24 months after (N)ACT and there was no clinically meaningful persistence of fatigue severity in OL-treated patients. 
700 1 |a Bandos, Hanna  |e VerfasserIn  |4 aut 
700 1 |a Španić, Tanja  |e VerfasserIn  |4 aut 
700 1 |a Friedman, Sue  |e VerfasserIn  |4 aut 
700 1 |a Müller, Volkmar  |e VerfasserIn  |4 aut 
700 1 |a Kuemmel, Sherko  |e VerfasserIn  |4 aut 
700 1 |a Delaloge, Suzette  |e VerfasserIn  |4 aut 
700 1 |a Brain, Etienne  |e VerfasserIn  |4 aut 
700 1 |a Toi, Masakazu  |e VerfasserIn  |4 aut 
700 1 |a Yamauchi, Hideko  |e VerfasserIn  |4 aut 
700 1 |a de Dueñas, Eduardo-M.  |e VerfasserIn  |4 aut 
700 1 |a Armstrong, Anne  |e VerfasserIn  |4 aut 
700 1 |a Im, Seock-Ah  |e VerfasserIn  |4 aut 
700 1 |a Song, Chuan-gui  |e VerfasserIn  |4 aut 
700 1 |a Zheng, Hong  |e VerfasserIn  |4 aut 
700 1 |a Sarosiek, Tomasz  |e VerfasserIn  |4 aut 
700 1 |a Sharma, Priyanka  |e VerfasserIn  |4 aut 
700 1 |a Geng, Cuizhi  |e VerfasserIn  |4 aut 
700 1 |a Fu, Peifen  |e VerfasserIn  |4 aut 
700 1 |a Rhiem, Kerstin  |e VerfasserIn  |4 aut 
700 1 |a Frauchiger-Heuer, Heike  |e VerfasserIn  |4 aut 
700 1 |a Wimberger, Pauline  |d 1971-  |e VerfasserIn  |0 (DE-588)121614859  |0 (DE-627)705574733  |0 (DE-576)292800061  |4 aut 
700 1 |a t'Kint de Roodenbeke, Daphné  |e VerfasserIn  |4 aut 
700 1 |a Liao, Ning  |e VerfasserIn  |4 aut 
700 1 |a Goodwin, Annabel  |e VerfasserIn  |4 aut 
700 1 |a Chakiba-Brugère, Camille  |e VerfasserIn  |4 aut 
700 1 |a Friedlander, Michael  |e VerfasserIn  |4 aut 
700 1 |a Lee, Keun Seok  |e VerfasserIn  |4 aut 
700 1 |a Giacchetti, Sylvie  |e VerfasserIn  |4 aut 
700 1 |a Takano, Toshimi  |e VerfasserIn  |4 aut 
700 1 |a Henao-Carrasco, Fernando  |e VerfasserIn  |4 aut 
700 1 |a Virani, Shamsuddin  |e VerfasserIn  |4 aut 
700 1 |a Valdes-Albini, Frances  |e VerfasserIn  |4 aut 
700 1 |a Domchek, Susan M.  |e VerfasserIn  |4 aut 
700 1 |a Bane, Charles  |e VerfasserIn  |4 aut 
700 1 |a McCarron, Edward C.  |e VerfasserIn  |4 aut 
700 1 |a Mita, Monica  |e VerfasserIn  |4 aut 
700 1 |a Rossi, Giovanna  |e VerfasserIn  |4 aut 
700 1 |a Rastogi, Priya  |e VerfasserIn  |4 aut 
700 1 |a Fielding, Anitra  |e VerfasserIn  |4 aut 
700 1 |a Gelber, Richard D.  |e VerfasserIn  |4 aut 
700 1 |a Scheepers, Elsemieke D.  |e VerfasserIn  |4 aut 
700 1 |a Cameron, David  |e VerfasserIn  |4 aut 
700 1 |a Garber, Judy  |e VerfasserIn  |4 aut 
700 1 |a Geyer, Charles E.  |e VerfasserIn  |4 aut 
700 1 |a Tutt, Andrew N.J.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical oncology  |d Alexandria, Va. : American Society of Clinical Oncology, 1983  |g 42(2024), 11 vom: Apr., Seite 1288-1300  |h Online-Ressource  |w (DE-627)313116962  |w (DE-600)2005181-5  |w (DE-576)090887018  |x 1527-7755  |7 nnas  |a Patient-reported outcomes in OlympiA a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer 
773 1 8 |g volume:42  |g year:2024  |g number:11  |g month:04  |g pages:1288-1300  |g extent:13  |a Patient-reported outcomes in OlympiA a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer 
856 4 0 |u https://doi.org/10.1200/JCO.23.01214  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://ascopubs.org/doi/10.1200/JCO.23.01214  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20241209 
993 |a Article 
994 |a 2024 
998 |g 121614859  |a Wimberger, Pauline  |m 121614859:Wimberger, Pauline  |p 22 
999 |a KXP-PPN1911195921  |e 4633326945 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-"}],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Society of Clinical Oncology"}],"id":{"eki":["313116962"],"issn":["1527-7755"],"zdb":["2005181-5"]},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"42(2024), 11 vom: Apr., Seite 1288-1300","volume":"42","year":"2024","issue":"11","extent":"13","pages":"1288-1300"},"recId":"313116962","title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"disp":"Patient-reported outcomes in OlympiA a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancerJournal of clinical oncology"}],"id":{"doi":["10.1200/JCO.23.01214"],"eki":["1911195921"]},"recId":"1911195921","title":[{"title_sort":"Patient-reported outcomes in OlympiA","subtitle":"a Phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer","title":"Patient-reported outcomes in OlympiA"}],"name":{"displayForm":["Patricia A. Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Sherko Kuemmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Hideko Yamauchi, Eduardo-M. de Dueñas, Anne Armstrong, Seock-Ah Im, Chuan-gui Song, Hong Zheng, Tomasz Sarosiek, Priyanka Sharma, Cuizhi Geng, Peifen Fu, Kerstin Rhiem, Heike Frauchiger-Heuer, Pauline Wimberger, Daphné t'Kint de Roodenbeke, Ning Liao, Annabel Goodwin, Camille Chakiba-Brugère, Michael Friedlander, Keun Seok Lee, Sylvie Giacchetti, Toshimi Takano, Fernando Henao-Carrasco, Shamsuddin Virani, Frances Valdes-Albini, Susan M. Domchek, Charles Bane, Edward C. McCarron, Monica Mita, Giovanna Rossi, Priya Rastogi, Anitra Fielding, Richard D. Gelber, Elsemieke D. Scheepers, David Cameron, Judy Garber, Charles E. Geyer, and Andrew N.J. Tutt"]},"physDesc":[{"extent":"13 S."}],"language":["eng"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"February 1, 2024"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"roleDisplay":"VerfasserIn","family":"Ganz","role":"aut","given":"Patricia A.","display":"Ganz, Patricia A."},{"given":"Hanna","display":"Bandos, Hanna","roleDisplay":"VerfasserIn","family":"Bandos","role":"aut"},{"given":"Tanja","display":"Španić, Tanja","roleDisplay":"VerfasserIn","family":"Španić","role":"aut"},{"given":"Sue","display":"Friedman, Sue","roleDisplay":"VerfasserIn","family":"Friedman","role":"aut"},{"role":"aut","family":"Müller","roleDisplay":"VerfasserIn","display":"Müller, Volkmar","given":"Volkmar"},{"roleDisplay":"VerfasserIn","family":"Kuemmel","role":"aut","given":"Sherko","display":"Kuemmel, Sherko"},{"given":"Suzette","display":"Delaloge, Suzette","roleDisplay":"VerfasserIn","family":"Delaloge","role":"aut"},{"given":"Etienne","display":"Brain, Etienne","family":"Brain","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","family":"Toi","roleDisplay":"VerfasserIn","display":"Toi, Masakazu","given":"Masakazu"},{"display":"Yamauchi, Hideko","given":"Hideko","role":"aut","roleDisplay":"VerfasserIn","family":"Yamauchi"},{"role":"aut","roleDisplay":"VerfasserIn","family":"de Dueñas","display":"de Dueñas, Eduardo-M.","given":"Eduardo-M."},{"roleDisplay":"VerfasserIn","family":"Armstrong","role":"aut","given":"Anne","display":"Armstrong, Anne"},{"display":"Im, Seock-Ah","given":"Seock-Ah","role":"aut","roleDisplay":"VerfasserIn","family":"Im"},{"given":"Chuan-gui","display":"Song, Chuan-gui","family":"Song","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Hong","display":"Zheng, Hong","roleDisplay":"VerfasserIn","family":"Zheng","role":"aut"},{"family":"Sarosiek","roleDisplay":"VerfasserIn","role":"aut","given":"Tomasz","display":"Sarosiek, Tomasz"},{"role":"aut","family":"Sharma","roleDisplay":"VerfasserIn","display":"Sharma, Priyanka","given":"Priyanka"},{"display":"Geng, Cuizhi","given":"Cuizhi","role":"aut","family":"Geng","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Fu","role":"aut","given":"Peifen","display":"Fu, Peifen"},{"given":"Kerstin","display":"Rhiem, Kerstin","roleDisplay":"VerfasserIn","family":"Rhiem","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Frauchiger-Heuer","role":"aut","given":"Heike","display":"Frauchiger-Heuer, Heike"},{"family":"Wimberger","roleDisplay":"VerfasserIn","role":"aut","given":"Pauline","display":"Wimberger, Pauline"},{"given":"Daphné","display":"t'Kint de Roodenbeke, Daphné","family":"t'Kint de Roodenbeke","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Liao","roleDisplay":"VerfasserIn","role":"aut","given":"Ning","display":"Liao, Ning"},{"display":"Goodwin, Annabel","given":"Annabel","role":"aut","family":"Goodwin","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Chakiba-Brugère","role":"aut","given":"Camille","display":"Chakiba-Brugère, Camille"},{"given":"Michael","display":"Friedlander, Michael","roleDisplay":"VerfasserIn","family":"Friedlander","role":"aut"},{"display":"Lee, Keun Seok","given":"Keun Seok","role":"aut","family":"Lee","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Giacchetti","display":"Giacchetti, Sylvie","given":"Sylvie"},{"role":"aut","family":"Takano","roleDisplay":"VerfasserIn","display":"Takano, Toshimi","given":"Toshimi"},{"family":"Henao-Carrasco","roleDisplay":"VerfasserIn","role":"aut","given":"Fernando","display":"Henao-Carrasco, Fernando"},{"given":"Shamsuddin","display":"Virani, Shamsuddin","family":"Virani","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Valdes-Albini","role":"aut","given":"Frances","display":"Valdes-Albini, Frances"},{"display":"Domchek, Susan M.","given":"Susan M.","role":"aut","family":"Domchek","roleDisplay":"VerfasserIn"},{"given":"Charles","display":"Bane, Charles","family":"Bane","roleDisplay":"VerfasserIn","role":"aut"},{"display":"McCarron, Edward C.","given":"Edward C.","role":"aut","roleDisplay":"VerfasserIn","family":"McCarron"},{"roleDisplay":"VerfasserIn","family":"Mita","role":"aut","given":"Monica","display":"Mita, Monica"},{"roleDisplay":"VerfasserIn","family":"Rossi","role":"aut","given":"Giovanna","display":"Rossi, Giovanna"},{"given":"Priya","display":"Rastogi, Priya","family":"Rastogi","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Fielding","roleDisplay":"VerfasserIn","role":"aut","given":"Anitra","display":"Fielding, Anitra"},{"roleDisplay":"VerfasserIn","family":"Gelber","role":"aut","given":"Richard D.","display":"Gelber, Richard D."},{"display":"Scheepers, Elsemieke D.","given":"Elsemieke D.","role":"aut","family":"Scheepers","roleDisplay":"VerfasserIn"},{"role":"aut","family":"Cameron","roleDisplay":"VerfasserIn","display":"Cameron, David","given":"David"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Garber","display":"Garber, Judy","given":"Judy"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Geyer","display":"Geyer, Charles E.","given":"Charles E."},{"role":"aut","roleDisplay":"VerfasserIn","family":"Tutt","display":"Tutt, Andrew N.J.","given":"Andrew N.J."}],"note":["Gesehen am 09.12.2024"]} 
SRT |a GANZPATRICPATIENTREP1202